Xtandi (enzalutamide)

February 11, 2020February 13, 2020

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

News

Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), according to final data from a Phase 3 clinical trial. Developed by Pfizer and Astellas Pharma, Xtandi ... Read more

August 26, 2019

Request for Xtandi to Treat Metastatic Hormone-sensitive Prostate Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has agreed to review Astellas Pharma and Pfizer‘s application for Xtandi (enzalutamide), requesting its approved use be expanded to include men whose metastatic prostate ... Read more

January 27, 2019February 6, 2020

Xtandi Should Follow Zytiga for Treatment of Castration-resistant Prostate Cancer, Phase 2 Trial Shows

News

More men with castration-resistant prostate cancer saw their prostate cancer antigen (PSA) levels — a marker of the disease — decline when they took Xtandi (enzalutamide) after Zytiga (abiraterone acetate) ... Read more

January 7, 2019

Phase 2 Trial Assessing CPI-1205, Plus Xtandi, Begins Dosing Metastatic CRPC Patients

News

Constellation Pharmaceuticals has begun patient dosing in the second part of a Phase 1b/2 trial testing its investigational inhibitor CPI-1205, in combination with Xtandi (enzalutamide), for the second-line treatment of metastatic ... Read more

September 13, 2018

A.I.-guided Chemo Halts Disease Worsening in Patient with mPRPC, Study Reports

News

An artificial intelligence (A.I.) platform called CURATE.AI may be used to determine the optimal doses of investigational therapy ZEN-3694 and Xtandi (enzalutamide) to be given to patients with metastatic castration-resistant prostate ... Read more

July 5, 2018July 10, 2018

Xtandi May Not Improve Overall Survival in Specific Type of Prostate Cancer, Early Phase 3 Data Suggest

News

Treatment with Xtandi (enzalutamide) does not seem to improve overall survival in men with non-metastatic castration-resistant prostate cancer (CRPC), according to the first interim analysis of a Phase 3 clinical trial. These findings were published in ... Read more

February 12, 2018February 13, 2018

Xtandi Reduces Risk of Metastasis in Castration-resistant Prostate Cancer, Phase 3 Trial Shows

News

Treatment with Xtandi (enzalutamide) reduced the risk of metastasis or death in castration-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond the prostate, Pfizer and Japan-based Astellas Pharma recently ... Read more

June 21, 2017

Mechanism Identified in Cellular Change Driving Castration-Resistant Prostate Cancer

News

Researchers at Moffitt Cancer Center have revealed the mechanism that explains the transformation process of prostate cells into castration-resistant cancer cells. They’ve also identified a new drug candidate that targets ... Read more

May 17, 2017May 17, 2017

Blocking Aggressive Prostate Cancer’s Fat-burning Mechanism Overcomes Disease’s Resistance to Xtandi

News

A major problem treating an aggressive form of prostate cancer is that it develops resistance to the androgen therapies used to combat it. One solution could be targeting the cancer’s ... Read more

April 20, 2017April 20, 2017

QIAGEN to Market Test That Shows if Prostate Cancer Is Responding to Two Therapies

News

QIAGEN will begin marketing a test that Johns Hopkins University developed to detect whether advanced prostate cancer patients are failing to respond to the widely used therapies Zytiga (enzalutamide) and Xtandi ... Read more